Subepithelial Corneal Deposits Associated with Exemestane

Area of Science:

• Ophthalmology
• Oncology
• Pharmacology

Background:

• Aromatase inhibitors (AIs) like exemestane are commonly prescribed for hormone receptor-positive breast cancer.
• Long-term AI use necessitates monitoring for potential systemic and ocular side effects.

Observation:

• A 69-year-old female patient developed a new-onset floater.
• Incidental bilateral subepithelial corneal opacities were discovered during examination.
• The patient had been taking exemestane for breast cancer treatment.

Findings:

• Corneal deposits, specifically bilateral subepithelial opacities, were observed.
• These corneal changes are hypothesized to be secondary to exemestane use.
• A slight improvement in opacity density was noted 3 months after discontinuing the medication.

Implications:

• Exemestane may cause ocular side effects, including corneal opacities.
• Ophthalmologists should consider exemestane as a potential cause for corneal deposits in patients.
• Further research is needed to understand the ocular effects of aromatase inhibitors.